12-weeks, Multicentre, Randomized, Double-blind, Placebo-controlled, Exploratory, Pilot Study to Evaluate the Safety and Efficacy of Safinamide 200 mg OD, as add-on Therapy, in Patients With Possible or Probable Parkinsonian Variant of MSA
Phase of Trial: Phase II
Latest Information Update: 18 Nov 2019
Price : $35 *
At a glance
- Drugs Safinamide (Primary)
- Indications Multiple system atrophy; Parkinson's disease
- Focus Adverse reactions
- Sponsors Zambon SpA
- 17 Oct 2019 Status changed from not yet recruiting to recruiting.
- 07 Jun 2019 Planned number of patients changed from 30 to 48.
- 07 Jun 2019 Planned initiation date changed from 31 Mar 2019 to 31 Jul 2019.